FDA Could Change Rules on Peptides Despite Concerns: How Safe Are They?
Summary
An FDA advisory panel has recommended easing restrictions on certain peptides, substances made of amino acids, despite concerns about their safety and effectiveness. This recommendation could allow some pharmacies to make these peptides and give them to patients with prescriptions, but the FDA has not yet approved them as drugs.Key Facts
- The FDA advisory panel voted 8-6, with one abstention, to recommend adding peptides BPC-157, KPV, and TB-500 to a list that allows compounding pharmacies to make them.
- These peptides have become popular for claims like antiaging, muscle healing, and reducing inflammation, mostly promoted by wellness influencers.
- Scientists warn there is not enough evidence showing these peptides are safe or effective in humans.
- BPC-157 is based on amino acids from human gastric juice and shows some benefits in animal studies but lacks human clinical trials.
- KPV is a small peptide studied mostly in cell and animal models for reducing inflammation, with uncertain effects in humans.
- TB-500 is linked to tissue repair in animal studies but has little human research, and concerns remain about the differences from naturally occurring peptides.
- Health Secretary Robert F. Kennedy Jr. supports peptides and has added panel members who have business interests in them.
- The FDA is not bound to accept the panel’s recommendation but often follows it.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.
